Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for determining binding rate of proteoglycan protein binding site in proteoglycan protein binding vaccine

A polysaccharide-protein-conjugated vaccine technology, applied in measuring devices, instruments, scientific instruments, etc., can solve the problem of no testing method

Active Publication Date: 2020-10-30
SHIMADZU (CHINA) CO LTD +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the detoxification of the carrier protein and the binding rate of the polysaccharide-protein binding site directly affect the quality of the polysaccharide-protein conjugated vaccine, there is no test method reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining binding rate of proteoglycan protein binding site in proteoglycan protein binding vaccine
  • Method for determining binding rate of proteoglycan protein binding site in proteoglycan protein binding vaccine
  • Method for determining binding rate of proteoglycan protein binding site in proteoglycan protein binding vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1 Determination of Polysaccharide Protein Binding Site Binding Rate in Polysaccharide Protein Binding Vaccine Taking Tetanus Toxoid as Carrier

[0084] 1. Experimental instruments and equipment: high-pressure binary pump, degasser, autosampler, column thermostat and triple quadrupole mass spectrometer.

[0085] 2. Experimental reagents: standard tetanus toxoid (1000 μg / L), 4-valent meningitis vaccine, TCEP, iodoacetamide (IAA), ammonium bicarbonate, RapiGest TM , trypsin, tetanus toxoid-based 4-valent meningitis vaccine, Hib vaccine and 13-valent pneumococcal vaccine. Meningitis vaccines A, W, C, Y, Hib vaccine, 13-valent pneumococcal vaccines 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F.

[0086] 3. Detection conditions:

[0087] Chromatographic conditions:

[0088] Chromatographic column: stationary phase 1 (biocompatible C18 chromatographic column);

[0089] Mobile phase: A: acetic acid aqueous solution (the volume ratio of acetic acid to water ...

Embodiment 2

[0134] Example 2 Determination of the binding rate of the polysaccharide protein binding site in the polysaccharide protein conjugate vaccine with CRM197 protein as the carrier

[0135] 1. Experimental instruments and equipment: high-pressure binary pump, degasser, autosampler, column thermostat and triple quadrupole mass spectrometer.

[0136] 2. Experimental reagents: CRM197 protein standard (100 μg / L), TCEP, iodoacetamide (IAA), ammonium bicarbonate, urea, trypsin, meningitis vaccine A, W, C, Y with CRM197 protein as the carrier , Hib vaccine, 13-valent pneumonia vaccine 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A and 23F.

[0137] 3. Detection conditions:

[0138] Chromatographic conditions:

[0139] Chromatographic column: stationary phase 2 (biocompatible C8 column);

[0140] Mobile phase: A: acetic acid aqueous solution (the volume ratio of acetic acid to water is 1:1000); B: acetic acid-acetonitrile mixture (the volume ratio of acetic acid to acetonitrile is 1:100...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for determining a binding rate of a proteoglycan protein binding site in a proteoglycan protein conjugate vaccine. The method comprises the following steps of: (1) carrying out enzymolysis on a standard substance; (2) carrying out solid-phase extraction to enrich a target peptide fragment; (3) performing high performance liquid chromatography tandem mass spectrometry analysis; (4) drawing a standard curve to obtain a standard working curve equation; (5) detecting a sample, and calculating to obtain the concentration of each characteristic peptide fragment in the sample; and (6) calculating a proteoglycan binding rate of each characteristic peptide fragment and a protein residue rate of each site. According to the method, the multi-site quantitative monitoring of the proteoglycan protein binding rate of the proteoglycan protein conjugate vaccine is achieved, the tetanus protein relates to 20 monitoring sites, and the CRM197 relates to 16 monitoring sites; the method not only can detect the residual protein content, but further can evaluate the binding rate of the proteoglycan protein binding site of the proteoglycan protein conjugate vaccine, can beused for researching polysaccharide or proteoglycan protein conjugate vaccines with the same protein residual rate but different activity and toxicity, and can provide a direct monitoring method for improving a proteoglycan protein binding process.

Description

technical field [0001] The invention relates to a method for determining the binding rate of polysaccharide-protein binding sites in polysaccharide-protein binding vaccines, belonging to the technical field of vaccine quality evaluation. Background technique [0002] Polysaccharide-protein conjugate vaccines are a type of vaccine formed by combining polysaccharides with proteins through chemical bonds. Proteins used in polysaccharide-protein conjugate vaccines are called protein carriers. Commonly used protein carriers include CRM197 protein, diphtheria toxoid (ie formaldehyde-detoxified diphtheria protein) and tetanus toxoid (ie formaldehyde-detoxified tetanus protein). Common polysaccharide-protein conjugate vaccines include quadrivalent meningitis vaccine (A, C, W, Y), Hib vaccine and 13-valent pneumonia polysaccharide vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C , 19F, 19A and 23F). Compared with polysaccharide vaccines, polysaccharide-protein conjugate vaccines have ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02G01N30/06
CPCG01N30/02G01N30/06G01N2030/027G01N2030/062
Inventor 龙珍李茂光李月琪李亚南李长坤毛琦琦黄涛宏许美凤
Owner SHIMADZU (CHINA) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com